Mdxhealth第三季收入2270万美元与去年持平：净亏损1230万美元、前九月收入7380万美元增9%
泌尿科精准诊断公司 Mdxhealth 于2026年11月12日公布截至2026年9月30日的第三季业绩。公司称，持续经营业务第三季收入为2270万美元，与上年同期持平。
公司第三季营业亏损为810万美元，上年同期为440万美元；公司称，营业亏损扩大主要源于与 ExoDx 收购相关的营业支出增加。
第三季净亏损为1230万美元，同比增加26%。调整后息税折旧摊销前利润（EBITDA）为负630万美元，上年同期为负90万美元。
收入构成方面，公司称第三季收入中79%来自组织类检测，上年同期该比例为92%。
今年前九个月，公司收入增长9%至7380万美元，上年同期为6770万美元。公司说明，业绩不含已终止经营的 Resolve mdx，该业务在当期与上年同期均按终止经营列报。
上述数字均出自 Mdxhealth 经 GlobeNewswire 发布的公司业绩公告原文。
关联：MDxHealth三季度初步营收约2270万美元 暂停全年1.10亿至1.15亿美元收入指引
Mdxhealth Third-Quarter Revenue Flat at $22.7 Million With Net Loss of $12.3 Million
Mdxhealth, the urology-focused precision diagnostics company, announced financial results on November 12, 2026 for the third quarter ended September 30, 2026. The company said revenue from continuing operations was $22.7 million, flat compared with the prior-year period.
Operating loss was $8.1 million, compared with $4.4 million in the third quarter of 2025, primarily due to increased operating expenses related to the ExoDx acquisition, the company said.
Net loss was $12.3 million, an increase of 26 percent over the prior-year period. Adjusted EBITDA was negative $6.3 million, compared with negative $0.9 million a year earlier.
Revenue in the third quarter of 2026 and 2025 was comprised of 79 percent and 92 percent from tissue-based tests, respectively, the company said.
For the nine months ended September 30, 2026, revenue increased 9 percent to $73.8 million, compared with $67.7 million a year earlier. Results exclude Resolve mdx, which has been discontinued and accounted for as a discontinued operation.
All figures are from Mdxhealth's own earnings release distributed via GlobeNewswire.
Related: MDxHealth preliminary third-quarter revenue report
来源：Mdxhealth 公司
发布：GSM·美国（发布链接）
图片来源：医学诊断实验室内的分析仪与技术人员。／Analyzers and technicians in a medical diagnostics laboratory.（Esculab，CC0，Wikimedia Commons）
GSM Global · 本篇英文版 English edition of this story
